Optimizing letermovir timing: Day +5 to +8 post haplo-HSCT minimizes EBV dnaemia without compromising CMV prophylaxis (ASH 2025) - Nov 4, 2025 - Abstract #abs25-11526; 2500; Pres time: Dec 6, 2025; 05:30 PM - 07:30 PM; Location: OCCC - West Halls B3-B4; "These findings suggest that day +5 to +8 may represent the optimal window forinitiating LTV prophylaxis to balance effective CMV prevention while minimizing the risk of EBVreactivation. Further prospective validation is needed."
Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia
|
|
Xingyu Cao1; Yue Lu1; Jian-Ping Zhang1; Zhijie Wei1; Deyan Liu1; Min Xiong1; Yanli Zhao1; Jiarui Zhou1; Ruijuan Sun1; Mengyuan Niu2; Fangmin Pan2; Jing Long2; Peihua Lu1
|